uniQure NV股票讨论

$uniQure NV (QURE.US)$ uniQure宣布对AMt-260进行难治性颞叶癫痫GenTLE I/IIa临床试验的首位患者进行了投药
4分钟前，东部时间上午7:05
通过GLOBENEWSWIRE

$CuriosityStream (CURI.US)$
我选择了错误的Curi！哈哈，但两者都不错。
$uniQure NV (QURE.US)$

$uniQure NV (QURE.US)$ $Apogee Enterprises (APOG.US)$ $Capricor Therapeutics (CAPR.US)$ $noco-noco (NCNC.US)$ $向上融科 (TIGR.US)$ $JBDI Holdings (JBDI.US)$ $Snail (SNAL.US)$ $Cue Biopharma (CUE.US)$ $Entero Therapeutics (ENTO.US)$ $Power REIT (PW.US)$ $福特汽车 (F.US)$ $Beneficient (BENF.US)$ $Phoenix Motor (PEV.US)$ $香颂国际 (CHSN.US)$
📊⚡️📊

$uniQure NV (QURE.US)$
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) announced that the U.S. FDA has granted Orphan Drug Designation to AMT-191, their investigational gene therapy for Fabry disease. This follows the dosing of the first patient in a U.S. multi-center, open-label Phase I/IIa trial in August 2024. AMT-191 is a one-time intravenously administered AAV5-based gene therapy targeting the liver to produce G...

$uniQure NV (QURE.US)$
uniQure宣布AMt-191用于法布病治疗的I/IIa临床试验已开始给第一个患者进行剂量投放。
uniQure N.V.（NASDAQ：QURE）已开始对AMt-191进行法布瑞病治疗的I/IIa期临床试验的剂量给药。在美国进行的多中心、开放标签试验将评估两个剂量递增队列的安全性、耐受性和早期疗效迹象。AMt-191是基于AAV5的基因疗法，可以传递α半乳糖苷酶（GLA）转基因至人体细胞内。

$uniQure NV (QURE.US)$ 糟糕

$uniQure NV (QURE.US)$ 开空内幕人员正在抛售

$uniQure NV (QURE.US)$ 回到原点

$uniQure NV (QURE.US)$ 零支撑位.. 什么鬼！